Company: PGEN
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001356090-25-000007
Chunk: 100

Company: PRECIGEN, INC.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 1A
Chunk 100
---
 compliance with the minimum bid price requirement or to meet the other applicable continued listing requirements in the future and Nasdaq determines to delist our common stock, the delisting could adversely affect the market price and liquidity of our common stock, reduce our ability to raise additional capital and result in operational challenges and damage to investor relations and market reputation.

Our quarterly and annual operating results may fluctuate in the future. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline.

Our financial condition and operating results have varied significantly in the past and may continue to fluctuate from quarter to quarter and year to year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following factors, as well as other factors described elsewhere in this Annual Report: 

•our ability to achieve or maintain profitability;

•the outcomes of our research programs, clinical trials, or other product development and approval processes;

•our ability to develop and successfully commercialize our products;

•the timing, receipt, and amount of any payments received in connection with upfront, milestone, and sale and royalty payments, if any; 

62

•our ability to successfully scale up production of our commercial products and customer acceptance thereof;

•our ability to enter into strategic transactions;

•our ability to develop and maintain our technologies;

•our ability to manage our growth;

•risks associated with the international aspects of our business;

•our ability to accurately report our financial results in a timely manner;

•our dependence on, and the need to attract and retain, key management, and other personnel;

•our ability to obtain, protect and enforce our intellectual property rights;

•our ability to prevent the theft or misappropriation of our intellectual property, know-how or technologies;

•the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes;

•potential advantages that our competitors and potential competitors may have in securing funding or developing competing technologies or products;

•our ability to obtain additional capital that may be necessary to expand our business;

•business interruptions such as power outages and other natural disasters;

•our ability to integrate any businesses or technologies we may acquire with our business;

•negative public opinion and increased regulatory scrutiny of gene and cell therapies;

•the impact of new accounting pronouncements on our current and future operating results;

•our ability to use our net operating loss